Tratamiento de las complicaciones cardiológicas más frecuentes en pacientes con cáncer

Nelson Alfredo Campos Vera; Eduardo Rivas Estany; Luccy Elena Zambrano Mendoza

Authors

Nelson Alfredo Campos Vera Universidad Técnica de Manabí https://orcid.org/0000-0001-9139-1809
Eduardo Rivas Estany Instituto de Cardiología y Cirugía Cardiovascular: La Habana, La Habana, CU https://orcid.org/0000-0002-5484-6111
Luccy Elena Zambrano Mendoza Universidad Técnica de Manabí https://orcid.org/0009-0009-3766-8390

Abstract

Introducción: Con el éxito del tratamiento del cancer , existe un alto riesgo de cardiotoxicidad que se ve reflejado en el notable aumento de casos relacionados a efectos adversos cardiológicos, generando un contexto donde se explica que casi la mitad de la mortalidad por cáncer se deba a enfermedad cardiovascular. Objetivo: Determinar el manejo de las complicaciones cardiológicas en pacientes con cáncer. Metodología: Se realizo una revisión bibliográfica cualitativa de tipo observacional, analítica y descriptiva, sobre tratamiento de las complicaciones cardiológicas en pacientes con cáncer. Resultados: las complicaciones cardiovasculares pueden variar según los medicamentos contra el cáncer, las dosis, el uso en combinación con otros agentes o la radioterapia y los factores de riesgo subyacentes del paciente. Conclusiones: El manejo de las complicaciones cardiológicas debe ser seleccionado con cautela para evitar mayores descompensaciones, donde la prevención de la cardiotoxicidad es un elemento fundamental.

Downloads

Download data is not yet available.

References

1. Toste JC. Cardio-oncology: Understanding the different mechanisms of cardiovascular toxicity. Rev Port Cardiol. 2022;41(7):587–97.

2. Kozhukhov SM, Dovganych N V, Smolanka II, Lygyrda OF, Bazyka OY, Lyalkin SA, et al. CARDIOTOXICITY RISK PREDICTION IN BREAST CANCER PATIENTS. Probl radiatsiinoi medytsyny ta radiobiolohii. 2021 Dec;26:498–512.

3. de Wall C, Bauersachs J, Berliner D. Cardiooncology—dealing with modern drug treatment, long-term complications, and cancer survivorship. Clin Exp Metastasis. 2021;38(4):361–71.

4. Lax J, Piñeiro D. Consenso de diagnóstico, prevención y tratamiento de la cardiotoxicidad por tratamiento médico del cáncer. Rev Argent Cardiol. 2013;81(6):530–6.

5. Jeong D, Gladish G, Chitiboi T, Fradley MG, Gage KL, Schiebler ML. MRI in cardio‐oncology: A review of cardiac complications in oncologic care. J Magn Reson Imaging. 2019;50(5):1349–66.

6. Tocchetti CG, Ameri P, de Boer RA, D’Alessandra Y, Russo M, Sorriento D, et al. Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart. Cardiovasc Res. 2020;116(11):1820–34.

7. Willems RAL, Winckers K, Biesmans C, de Vos-Geelen J, ten Cate H. Evolving data on cardiovascular complications in cancer. Thromb Res. 2022;213:S87–94.

8. Boudoulas KD, Triposkiadis F, Gumina R, Addison D, Iliescu C, Boudoulas H. Cardiovascular Disease, Cancer, and Multimorbidity Interactions: Clinical Implications. Cardiology. 2022;147(2):196–206.

9. Fabiani I, Panichella G, Aimo A, Grigoratos C, Vergaro G, Pugliese NR, et al. Subclinical cardiac damage in cancer patients before chemotherapy. Heart Fail Rev. 2022;27(4):1091–104.

10. Liang Z, He Y, Hu X. Cardio-Oncology: Mechanisms, Drug Combinations, and Reverse Cardio-Oncology. Int J Mol Sci. 2022;23(18):10617.

11. Totzeck M, Schuler M, Stuschke M, Heusch G, Rassaf T. Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease. Int J Cardiol. 2019;280:163–75.

12. Velásquez CA, González M, García-Orjuela MG, Jaramillo N. Enfermedad cardiaca inducida por radioterapia. Rev Colomb Cardiol. 2018;25(1):74–9.

13. Avellana P, Santos D, Antonietti L, Sampere T, Pocoví A, Domenichini E, et al. An Introduction to Chemotherapy-Related Major Complications a Cardiologist Must Face. Rev Argent Cardiol. 2007;75:55–60.

14. Gervaso L, Dave H, Khorana AA. Venous and Arterial Thromboembolism in Patients With Cancer. Jacc Cardioncology. 2021;3(2):173–90.

15. Zamorano JL, Gottfridsson C, Asteggiano R, Atar D, Badimon L, Bax JJ, et al. The cancer patient and cardiology. Eur J Heart Fail. 2020;22(12):2290–309.

16. Yeh ETH, Bickford CL. Cardiovascular Complications of Cancer Therapy. J Am Coll Cardiol. 2009;53(24):2231–47.

17. Chang H-M, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular Complications of Cancer Therapy. J Am Coll Cardiol. 2017;70(20):2536–51.

18. Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020 Aug;17(8):474–502.

19. Cohen JB, Brown NJ, Brown S-A, Dent S, van Dorst DCH, Herrmann SM, et al. Cancer Therapy–Related Hypertension: A Scientific Statement From the American Heart Association. Hypertension. 2023;80.

20. Yang H, Bhoo-Pathy N, Brand JS, Hedayati E, Grassmann F, Zeng E, et al. Risk of heart disease following treatment for breast cancer – results from a population-based cohort study. Elife. 2022;11.

21. Plana JC. La quimioterapia y el corazón. Rev Española Cardiol. 2011;64(5):409–15.

22. Zito C, Manganaro R, Ciappina G, Spagnolo CC, Racanelli V, Santarpia M, et al. Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do. Cancers (Basel). 2022;14(21):5403.

23. Martín García A, Mitroi C, Mazón Ramos P, García Sanz R, Virizuela JA, Arenas M, et al. Stratification and management of cardiovascular risk in cancer patients. Rev Española Cardiol. 2021;74(5):438–48.

24. Benítez FDM, Noyola AG. Complicaciones Cardiovasculares Postoperatorias en Cirugía Mayor Oncológica. Rev Cuba deCardiología yCirugía Cardiovasc. 2016;22(1):62–9.

25. Velásquez CA, Berrouet MC, González M, Jaramillo N. Cardiotoxicidad inducida por la quimioterapia desde las bases moleculares hasta la perspectiva clínica. Rev Colomb Cardiol. 2016;23(2):104–11.

26. Avila MS, Siqueira SRR, Ferreira SMA, Bocchi EA. Prevention and Treatment of Chemotherapy-Induced Cardiotoxicity. Methodist Debakey Cardiovasc J. 2019;15(4):267–73.

27. Garcia-Garduño TC, Padilla-Gutierrez JR, Cambrón-Mora D, Valle Y. RAAS: A Convergent Player in Ischemic Heart Failure and Cancer. Int J Mol Sci. 2021 Jul;22(13).

28. Peixoto R, Pereira M de L, Oliveira M. Beta-Blockers and Cancer: Where Are We? Pharmaceuticals (Basel). 2020 May;13(6).

29. van Dorst DCH, Dobbin SJH, Neves KB, Herrmann J, Herrmann SM, Versmissen J, et al. Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients. Circ Res. 2021 Apr;128(7):1040–61.

30. Das D, Asher A, Ghosh AK. Cancer and Coronary Artery Disease: Common Associations, Diagnosis and Management Challenges. Curr Treat Options Oncol. 2019 May;20(6):46.

31. Han X-J, Li J-Q, Khannanova Z, Li Y. Optimal management of coronary artery disease in cancer patients. Chronic Dis Transl Med. 2019 Dec;5(4):221–33.

32. Essa H, Wright DJ, Dobson R, Lip GYH. Chemotherapy-Induced Arrhythmia - Underrecognized and Undertreated. Am J Med. 2021 Oct;134(10):1224-1231.e1.

33. Vrontikis A, Carey J, Gilreath JA, Halwani A, Stephens DM, Sweetenham JW. Proposed Algorithm for Managing Ibrutinib-Related Atrial Fibrillation. Oncology (Williston Park). 2016 Nov;30(11):970–4, 980–1, C3.

34. Porta‐Sánchez A, Gilbert C, Spears D, Amir E, Chan J, Nanthakumar K, et al. Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review. J Am Heart Assoc. 2017 Dec;6(12).

35. Kim PY, Irizarry-Caro JA, Ramesh T, Iliescu C, Lopez-Mattei JC. How to Diagnose and Manage QT Prolongation in Cancer Patients. JACC CardioOncology. 2021 Mar;3(1):145–9.

36. Baracaldo-Santamaría D, Llinás-Caballero K, Corso-Ramirez JM, Restrepo CM, Dominguez-Dominguez CA, Fonseca-Mendoza DJ, et al. Genetic and Molecular Aspects of Drug-Induced QT Interval Prolongation. Int J Mol Sci. 2021 Jul;22(15):8090.

37. Bonaca MP, Olenchock BA, Salem J-E, Wiviott SD, Ederhy S, Cohen A, et al. Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology. Circulation. 2019 Jul;140(2):80–91.

38. Matzen E, Bartels LE, Løgstrup B, Horskær S, Stilling C, Donskov F. Immune checkpoint inhibitor-induced myocarditis in cancer patients: a case report and review of reported cases. Cardio-Oncology. 2021 Dec;7(1):27.

39. Landes U, Iakobishvili Z, Vronsky D, Zusman O, Barsheshet A, Jaffe R, et al. Transcatheter Aortic Valve Replacement in Oncology Patients With Severe Aortic? Stenosis. JACC Cardiovasc Interv. 2019 Jan;12(1):78–86.

40. Ghosh AK, Uk M, Card M, Crake T, Manisty C, Uk M, et al. Pericardial Disease in Cancer Patients. 2018;

41. Hu J-R, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res. 2019 Apr;115(5):854–68.

42. Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018;19(9):e447–58.

43. Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surg. Eur Heart J. 2015 Nov;36(42):2921–64.

44. Kirkpatrick EC. Pulmonary Hypertension as a Complication of Pediatric Cancer. Glob Pediatr Heal. 2021;8:2333794X211009094.

45. Omland T, Heck SL, Gulati G. The Role of Cardioprotection in Cancer? Therapy Cardiotoxicity: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncology. 2022 Mar;4(1):19–37.

46. Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D, et al. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA Cancer J Clin [Internet]. 2016 Jul 1 [cited 2023 Feb 2];66(4):309–25. Available from: https://onlinelibrary.wiley.com/doi/full/10.3322/caac.21341

47. Bojan A, Torok-Vistai T, Parvu A. Assessment and Management of Cardiotoxicity in Hematologic Malignancies. Dis Markers [Internet]. 2021 [cited 2023 Feb 2];2021. Available from: /pmc/articles/PMC7875649/

48. Kendall SJ, Langley JE, Aghdam M, Crooks BN, Giacomantonio N, Heinze-Milne S, et al. The Impact of Exercise on Cardiotoxicity in Pediatric and Adolescent Cancer Survivors: A Scoping Review. Curr Oncol [Internet]. 2022 Sep 1 [cited 2023 Feb 2];29(9):6350. Available from: /pmc/articles/PMC9497997/

49. Vejpongsa P, Yeh ETH. Prevention of Anthracycline-Induced Cardiotoxicity: Challenges and Opportunities. J Am Coll Cardiol. 2014 Sep 2;64(9):938–45.

50. Armenian S, Bhatia S. Predicting and Preventing Anthracycline-Related Cardiotoxicity. Am Soc Clin Oncol Educ B. 2018 May 23;(38):3–12.

51. Padegimas A, Clasen S, Ky B. Cardioprotective Strategies to Prevent Breast Cancer Therapy-Induced Cardiotoxicity. Trends Cardiovasc Med [Internet]. 2020 Jan 1 [cited 2023 Feb 2];30(1):22. Available from: /pmc/articles/PMC7287268/

52. Podyacheva E, Toropova Y. Nicotinamide Riboside for the Prevention and Treatment of Doxorubicin Cardiomyopathy. Opportunities and Prospects. Nutrients [Internet]. 2021 Oct 1 [cited 2023 Feb 2];13(10). Available from: /pmc/articles/PMC8538727/

53. Jurczyk M, Król M, Midro A, Kurnik-łucka M, Poniatowski A, Gil K. Cardiotoxicity of Fluoropyrimidines: Epidemiology, Mechanisms, Diagnosis, and Management. J Clin Med [Internet]. 2021 Oct 1 [cited 2023 Feb 2];10(19):4426. Available from: /pmc/articles/PMC8509845/

54. Timm KN, Tyler DJ. The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity. Cardiovasc Drugs Ther [Internet]. 2020 Apr 1 [cited 2023 Feb 2];34(2):255. Available from: /pmc/articles/PMC7125062/